Connect
MJA
MJA

Discrepancies in genetic testing results for coeliac disease: call for standardised testing and reporting

A James M Daveson, Michael Varney, Kate E Jackson and Jason A Tye-Din
Med J Aust 2017; 207 (4) || doi: 10.5694/mja17.00314
Published online: 21 August 2017

To the Editor:

The full article is accessible to AMA
members and paid subscribers.
Login to MJA or subscribe now.

LOGIN TO MJA TO DOWNLOAD
SUBSCRIBE NOW
ACCESS VIA WILEY ONLINE launch

  • 1 University of Queensland, Brisbane, QLD
  • 2 Wesley Medical Research, Brisbane, QLD
  • 3 St Andrew's War Memorial Hospital, Brisbane, QLD
  • 4 Australian Red Cross Blood Service, Melbourne, VIC
  • 5 Mackay Hospital and Health Service, Mackay, QLD
  • 6 Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC
  • 7 Royal Melbourne Hospital, Melbourne, VIC


Correspondence: james.daveson@uq.edu.au
Competing interests:

Jason Tye-Din is a co-inventor of patents pertaining to the use of gluten peptides in therapeutics, diagnostics and non-toxic gluten; a shareholder of Nexpep; and consultant to ImmusanT. A James Daveson has performed clinical trials for ImmusanT.

  • 1. Tye-Din JA, Cameron DJ, Daveson AJ, et al. Appropriate clinical use of human leukocyte antigen typing for coeliac disease: an Australasian perspective. Intern Med J 2015; 45: 441-450.

Author
remove_circle_outline Delete Author
add_circle_outline Add Author
Comment
Do you have any competing interests to declare? *
I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article
Online responses are no longer available. Please refer to our instructions for authors page for more information.